` ADCT (ADC Therapeutics SA) vs S&P 500 Comparison - Alpha Spread

ADCT
vs
S&P 500

Over the past 12 months, ADCT has underperformed S&P 500, delivering a return of 3% compared to the S&P 500's 10% growth.

Stocks Performance
ADCT vs S&P 500

Loading
ADCT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ADCT vs S&P 500

Loading
ADCT
S&P 500
Difference
www.alphaspread.com

Performance By Year
ADCT vs S&P 500

Loading
ADCT
S&P 500
Add Stock

Competitors Performance
ADC Therapeutics SA vs Peers

S&P 500
ADCT
ABBV
AMGN
GILD
VRTX
Add Stock

ADC Therapeutics SA
Glance View

Market Cap
274.7m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
5.21 USD
Undervaluation 47%
Intrinsic Value
Price
Back to Top